DNA wrapped around histones
Decoder
By Julie Grisham, MS, Science Writer/Editor  |  Tuesday, October 14, 2014

Physician-scientist Omar Abdel-Wahab explains epigenetics, a growing field based on the study of genetic changes that are not part of the DNA code, and how it relates to cancer.

Pictured: Ping Chi
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Thursday, October 9, 2014

Genetic analysis reveals biomarkers and possible drug targets for malignant peripheral nerve sheath tumors.

Pictured: Gabriela Chiosis
Finding
By Celia Gittelson, BA  |  Thursday, July 17, 2014

A small molecule discovered at MSK called PU-H71 blocks the growth of cancer cells and enables doctors to image tumors.

Pictured: David Solit
Profile
By Julie Grisham, MS, Science Writer/Editor  |  Tuesday, May 27, 2014

David Solit, Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, discusses how working with cancer patients drives him to develop more-effective, personalized cancer treatments.

Pictured: Mark Kris
Finding
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, May 21, 2014

A new study has found that driver mutations can be found in about two-thirds of lung adenocarcinomas, suggesting options for treatment with targeted therapies.

Pictured: José Baselga, Agnès Viale,  Michael Berger & David Solit
Announcement
By Eva Kiesler, PhD, Science Writer/Editor  |  Tuesday, May 20, 2014

With the creation of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering sets out to deliver on the promise of personalized medicine by creating better treatment options for all people with cancer.

pictured: Martin S. Tallman
Profile
By Maureen Salamon, BA, Freelance Writer  |  Monday, May 19, 2014

Leukemia Specialist Martin Tallman discusses how research has led to improvements in the treatment of leukemia and what challenges remain.

Pictured: William Tap
MSK at ASCO
By Media Staff  |  Thursday, May 15, 2014

New Memorial Sloan Kettering research demonstrates the powerful clinical benefit of giving patients a drug that targets the molecular abnormality driving the growth of a rare and debilitating joint disease.

Pictured: Richard Steingart
In the Clinic
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, March 19, 2014

Cancer treatments, both traditional treatments and newer targeted therapies, can lead to short-term and long-term heart problems.

Pictured: Diane Reidy
Feature
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, February 19, 2014

Cycle for Survival, Memorial Sloan Kettering’s nationwide indoor team cycling event, helps support research into rare cancers. Three researchers discuss how these funds benefit their research.

Pictured: Robert J. Motzer
In the Clinic
By Maureen Salamon, BA, Freelance Writer  |  Thursday, August 22, 2013

An international study led by Memorial Sloan Kettering found that pazopanib (Votrient®) controls cancer as effectively as sunitinib (Sutent®) while improving patients’ quality of life.

Pictured: Scott Armstrong, Michael Kuehn, Haijhua Chu, Monica Cusan & Andrei Kritsov
Profile
By Esther Napolitano, BS, Science Writer/Editor  |  Friday, July 12, 2013

Scott Armstrong specializes in the treatment of leukemia in children. His research focuses on the disease in children and adults.

Charles Sawyers, Kenneth Offit, and Larry Norton
Honor
By Eva Kiesler, PhD, Science Writer/Editor  |  Wednesday, May 22, 2013

Charles Sawyers, Larry Norton, and Kenneth Offit are being honored with special awards at the annual meeting of the world’s leading professional organization for cancer physicians and researchers.

Pictured: Robert Motzer & Suzanne Gornell
Video
By Allyson Collins, MS, Science Writer/Editor  |  Wednesday, May 8, 2013

Our experts have participated in or led the development of five of the seven drugs approved by the US Food and Drug Administration for patients with advanced kidney cancer since 2005.

Pictured: Charles Sawyers
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Tuesday, April 30, 2013

Research suggests that a new drug could be effective in patients with prostate cancer who develop resistance to the targeted therapy enzalutamide.

Center News

Stay Informed

Get the latest information about cancer care and research every month.